In the T-ALL context, it has been demonstrated that pharmacological inhibition of Casein Kinase 2 (CK2) through CX-4945 may be an efficient treatment for a subset of T-ALLs displaying upregulation of the CK2/PI3K/Akt/mTOR axis via downmodulation of the ER stress/UPR signaling55. The gene discussed is MTOR; the disease is acute lymphoblastic leukemia.